Kikuchi Daiki, Ishii Yoshimasa, Saitou Masaru, Yamada Mutsuo, Takenoshita Seiichi
Dept. of General Surgery, Ohta Nishinouchi Hospital, Japan.
Gan To Kagaku Ryoho. 2011 Jul;38(7):1113-7.
We retrospectively examined patients with advanced gastric cancer who underwent S-1/CDDP combined neoadjuvant chemotherapy. Nine patients who had the factor of curative surgery deemed not feasible for advanced gastric cancer were enrolled. 80 mg/m2 of S-1 was given orally from days 1-14, and 60 mg/m2 of CDDP was administered on day 8. Patients were treated with a three-cycle protocol. When an adverse event greater than Grade 3 showed, we judged that chemotherapy could not be continued and surgery was performed. An anti-tumor effect on the imaging was found in all cases of PR. The histological effect was judged to be Grade 3 and pathological CR in two cases. In the postoperative period, all patients received adjuvant chemotherapy. S-1/CDDP combined neoadjuvant chemotherapy is a potential regimen for advanced gastric cancer.
我们回顾性研究了接受S-1/顺铂联合新辅助化疗的晚期胃癌患者。纳入了9例因晚期胃癌而被认为无法进行根治性手术的患者。S-1 80mg/m²于第1 - 14天口服，顺铂60mg/m²于第8天给药。患者接受三周期方案治疗。当出现大于3级的不良事件时，我们判断无法继续化疗并进行手术。所有PR病例在影像学上均发现有抗肿瘤作用。组织学疗效判定为3级，2例为病理完全缓解。术后所有患者均接受辅助化疗。S-1/顺铂联合新辅助化疗是晚期胃癌的一种潜在治疗方案。
Zotero 插件